Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy

被引：3

作者：

Bojanic, Kristina ^{[1
,2
]}

Curcic, Ines Bilic ^{[1
,3
,4
]}

Kuna, Lucija ^{[5
,6
]}

Kizivat, Tomislav ^{[1
,7
]}

Smolic, Robert ^{[1
,3
,4
]}

Lucic, Nikola Raguz ^{[1
,3
,8
]}

Kralik, Kristina ^{[9
]}

Seric, Vatroslav ^{[1
]}

Ivanac, Gordana ^{[10
]}

Tucak-Zoric, Sandra ^{[1
]}

Vcev, Aleksandar ^{[1
,4
,11
]}

Smolic, Martina ^{[1
,3
,8
]}

机构：

[1] JJ Strossmayer Univ Osijek, Fac Med Osijek, Dept Mineral Metab, Osijek 31000, Croatia

[2] Hlth Ctr Osijek, Dept Radiol, Osijek 31000, Croatia

[3] JJ Strossmayer Univ Osijek, Fac Med Osijek, Dept Pharmacol, Osijek 31000, Croatia

[4] Univ Hosp Osijek, Dept Med, Osijek 31000, Croatia

[5] JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Dept Biol, Osijek 31000, Croatia

[6] JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Dept Chem, Osijek 31000, Croatia

[7] Univ Hosp Osijek, Clin Inst Nucl Med & Radiat Safety, Osijek 31000, Croatia

[8] JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Dept Pharmacol, Osijek 31000, Croatia

[9] JJ Strossmayer Univ Osijek, Fac Med Osijek, Dept Med Stat & Med Informat, Osijek 31000, Croatia

[10] Univ Hosp Dubrava, Dept Diagnost & Intervent Radiol, Zagreb 10000, Croatia

[11] JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Dept Pathophysiol, Osijek 31000, Croatia

来源：

JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 09期

关键词：

aromatase inhibitors; bone density; breast neoplasms; Wnt signaling pathway; AROMATASE INHIBITORS; SCLEROSTIN LEVELS; AMERICAN SOCIETY; SERUM SCLEROSTIN; ADJUVANT TRIALS; DICKKOPF-1; TAMOXIFEN; DKK1; EXPRESSION; ESTROGEN;

D O I：

10.3390/jcm7090287

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aim: To determine the levels of Wnt inhibitors in patients treated with aromatase inhibitors (AIs) prior to therapy and to investigate their association with bone mineral density (BMD) and lifestyle parameters. Methods: 137 breast cancer patients were divided into a group treated with 1 mg of anastrozole and a group w/o anastrozole therapy. Serum concentrations of sclerostin and dickkopf1 (DKK1) were measured by ELISA. BMD was measured by dual-energy X-ray absorptiometry (DXA). Lifestyle factors were investigated by a self-reported questionnaire. Results: Sclerostin was significantly higher in the AI-treated group (31.8 pmol/L vs. 24.1 pmol/L; p < 0.001), whereas DKK1 was significantly lower in the AI-treated group (24.3 pmol/L vs. 26.02 pmol/L; p < 0.001). Total hip and femoral neck BMD were significantly lower in the AI-treated group. Conclusion: AI treatment was associated with increased levels of sclerostin and decreased levels of DKK1.

引用

页数：12

共 50 条

[1] Bone Mineral Density Screening Among Women with a History of Breast Cancer Treated with Aromatase Inhibitors
Spangler, Leslie
Yu, Onchee
Loggers, Elizabeth
Boudreau, Denise M.
JOURNAL OF WOMENS HEALTH, 2013, 22 (02) : 132 - 140
[2] Bone Mineral Density Screening in Invasive Breast Cancer Patients Treated with Anastrozole in Adjuvant Setting
Pai, K.
Gilani, S.
Brunt, A.
CLINICAL ONCOLOGY, 2017, 29 (06) : E102 - E103
[3] Bone mineral density and bone turnover in postmenopausal women treated for breast cancer
Waltman, Nancy L.
Ott, Carol D.
Twiss, Janice J.
Gross, Gloria J.
Lindsey, Ada M.
Moore, Timothy E.
CANCER NURSING, 2008, 31 (03) : 182 - 190
[4] Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole
Kalder, Matthias
Ziller, Volker
Kyvernitakis, Ioannis
Knoell, Dana
Hars, Olaf
Hadji, Peyman
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 915 - 923
[5] Bone mineral density in women with breast cancer and the impact of aromatase inhibitors
Saleh, B.
Gronland, N.
Singer, J.
Bradpiece, H.
Patel, A.
OSTEOPOROSIS INTERNATIONAL, 2006, 17 : 384 - 385
[6] Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole
Matthias Kalder
Volker Ziller
Ioannis Kyvernitakis
Dana Knöll
Olaf Hars
Peyman Hadji
Journal of Cancer Research and Clinical Oncology, 2013, 139 : 915 - 923
[7] Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer
Katsuhiko Nakatsukasa
Hiroshi Koyama
Yoshimi Ouchi
Kouichi Sakaguchi
Yoshifumi Fujita
Takayuki Matsuda
Makoto Kato
Eiichi Konishi
Tetsuya Taguchi
Journal of Bone and Mineral Metabolism, 2019, 37 : 301 - 306
[8] Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer
Nakatsukasa, Katsuhiko
Koyama, Hiroshi
Ouchi, Yoshimi
Sakaguchi, Kouichi
Fujita, Yoshifumi
Matsuda, Takayuki
Kato, Makoto
Konishi, Eiichi
Taguchi, Tetsuya
JOURNAL OF BONE AND MINERAL METABOLISM, 2019, 37 (02) : 301 - 306
[9] Bone mineral density in women with breast cancer
Kocaaga, Z.
Turan, Y.
Duransoy, A.
Gurgan, A.
OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S27 - S27
[10] Bone mineral density in women with breast cancer
Celik, O. Karakoyun
Turan, Y.
Kocaaga, Z.
Gurgan, A.
Duransoy, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →